Movatterモバイル変換


[0]ホーム

URL:


CN101747280B - Method for preparing detomidine and the intermediate thereof - Google Patents

Method for preparing detomidine and the intermediate thereof
Download PDF

Info

Publication number
CN101747280B
CN101747280BCN2008102037170ACN200810203717ACN101747280BCN 101747280 BCN101747280 BCN 101747280BCN 2008102037170 ACN2008102037170 ACN 2008102037170ACN 200810203717 ACN200810203717 ACN 200810203717ACN 101747280 BCN101747280 BCN 101747280B
Authority
CN
China
Prior art keywords
imidazoles
dimethylbenzoyl
reaction
detomidine
imidazole carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008102037170A
Other languages
Chinese (zh)
Other versions
CN101747280A (en
Inventor
李金亮
赵楠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Acebright Pharmaceuticals Group Co ltd
Shanghai Desano Pharmaceuticals Investment Co ltd
Shanghai Desano Chemical Pharmaceutical Co Ltd
Original Assignee
SHANGHAI DISAINUO CHEMICAL PHARMACEUTICAL CO Ltd
DISAINO MEDICINE DEVELOPMENT Co LTD SHANGHAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI DISAINUO CHEMICAL PHARMACEUTICAL CO Ltd, DISAINO MEDICINE DEVELOPMENT Co LTD SHANGHAIfiledCriticalSHANGHAI DISAINUO CHEMICAL PHARMACEUTICAL CO Ltd
Priority to CN2008102037170ApriorityCriticalpatent/CN101747280B/en
Publication of CN101747280ApublicationCriticalpatent/CN101747280A/en
Application grantedgrantedCritical
Publication of CN101747280BpublicationCriticalpatent/CN101747280B/en
Expired - Fee Relatedlegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Landscapes

Abstract

The invention provides a method for preparing detomidine and the intermediate thereof. The method for preparing the intermediate of the detomidine comprises the steps that: 4-imidazolecarboxamide is condensed with 2, 3-Dimethylbromobenzene to produce 4-(2, 3- dimethylbenzoyl)-imidazole. The 4-(2, 3- dimethylbenzoyl)-imidazole can be reduced to produce the detomidine. The method of the invention has cheap and easy-to-get raw materials, easy-to-control technological processes, high yield factor and low cost and is suitable for being produced in an industrialized manner.

Description

The method for preparing detomidine and intermediate thereof
Technical field
The present invention relates to prepare the method for detomidine and intermediate thereof.
Background technology
Detomidine (Detomidine) chemistry 4-(2, the 3-dimethyl benzyl) by name-1H-imidazoles, its structural formula is as follows:
Figure G2008102037170D00011
Detomidine is a veterinary anaesthetic drugs, and this medicine has calmness and analgesic activity to multiple animal, and is especially better to horse and Niu Xiaoguo.This medicine is the same with xylazine (Xylazine) with clonidine, also belongs to maincenter α _ 2 adrenergic receptor stimulants.
U.S. Pat 4443466 has been reported the synthetic method of detomidine, and synthetic route is as follows:
Figure G2008102037170D00012
The technology of above-mentioned patent report is a raw material with the imidazole aldehyde, with 2, and the condensation of 3-dimethyl bromobenzene, and then reduction generates detomidine.Because the raw material otan dipolymer of synthetic imidazole aldehyde is difficult to buy, and obtains the yield also low (26%) of imidazole aldehyde, with the synthetic detomidine raw materials cost height of this method.
Summary of the invention
The purpose of this invention is to provide a kind of method for preparing detomidine and intermediate thereof, to overcome the above-mentioned defective that prior art exists.
The method for preparing the detomidine intermediate of the present invention comprises the steps:
The 4-Imidazole carboxamide is suspended in the organic bases solvent, 60-70 ℃ adds 2 down, the Grignard reagent of 3-dimethyl bromobenzene, reacted then 1.5~2.5 hours, be cooled to 0-10 ℃, add the saturated ammonium chloride solution termination reaction, from reaction product, collect 4-(2 then, the 3-dimethylbenzoyl)-and imidazoles, be the intermediate for preparing detomidine;
Described 4-Imidazole carboxamide can be separated easily by imidazole carboxylate ammonia and obtain, and this method is not seen bibliographical information;
Described organic bases is selected from pyridine, triethylamine or 2,4-dimethylamino pyridine, most preferably pyridine;
4-Imidazole carboxamide and 2, the mol ratio of 3-dimethyl bromobenzene are 1:2-1:8, and that better is 1:4-1:6;
The synthetic method of detomidine of the present invention comprises the steps:
(a) the 4-Imidazole carboxamide is suspended in the organic bases solvent, 60-70 ℃ adds 2 down, the Grignard reagent of 3-dimethyl bromobenzene, reacted then 1.5~2.5 hours, be cooled to 0-10 ℃, add the saturated ammonium chloride solution termination reaction, from reaction product, collect 4-(2 then, the 3-dimethylbenzoyl)-and imidazoles, be the intermediate for preparing detomidine;
Described 4-Imidazole carboxamide can be separated easily by imidazole carboxylate ammonia and obtain;
Described organic bases is selected from pyridine, triethylamine or 2,4-dimethylamino pyridine, most preferably pyridine;
4-Imidazole carboxamide and 2, the mol ratio of 3-dimethyl bromobenzene are 1:2-1:8, and that better is 1:4-1:6;
(b) with 4-(2, the 3-dimethylbenzoyl)-imidazoles in organic solvent, alkaline matter exists down and the reduction reagent react, collects 4-(2, the 3-dimethyl benzyl)-1H-imidazoles (detomidine) then from reaction product;
Described organic solvent is selected from ethylene glycol 1,2-propylene glycol, 1, ammediol or neopentyl glycol;
Described alkaline matter is selected from potassium hydroxide, sodium hydroxide or calcium hydroxide, and the mol ratio of alkaline matter and 4-(2, the 3-dimethylbenzoyl)-imidazoles is 4-6:1;
Temperature of reaction is 120~200 ℃, and the reaction times is 1~2 hour, and 4-(2, the 3-dimethylbenzoyl)-imidazoles is 1:2~1:6 with the mol ratio of going back original reagent;
The described original reagent preferably water of going back is closed hydrazine;
Reaction expression is as follows:
Figure G2008102037170D00031
The method of synthetic detomidine of the present invention and intermediate thereof, raw material sources cheaply are easy to get, and technological operation is easy to control, the yield height, cost is low, is fit to suitability for industrialized production.
Embodiment
The present invention is further detailed explanation below in conjunction with embodiment.
Embodiment 1
The preparation of 4-Imidazole carboxamide:
4-imidazole carboxylate (8.5g) is joined in the water (68ml), blasts ammonia, reflux 6 hours, concentrate white solid, acetone (10ml) making beating refining white solid 6.7g, be the 4-Imidazole carboxamide, mother liquor reclaims to merge and can continue ammonia and separate.
Embodiment 2
The preparation of 4-(2, the 3-dimethylbenzoyl)-imidazoles
(45.0g 1.88mol) covers with the 150ml tetrahydrofuran (THF) with magnesium chips.With 2, (220.0ml 1.62mol) is dissolved in the 600ml tetrahydrofuran (THF) 3-dimethyl bromobenzene.This drips of solution is added in the magnesium chips, continues after the initiation reaction slowly to drip, keep refluxing.After adding, reflux is intact to reactive magnesium, reacts to obtain Grignard reagent in 30 minutes again.
(50.0g 0.45mol) is suspended in the 1500ml pyridine, is heated to 70 ℃, drips above-mentioned Grignard reagent, drips the back insulation reaction 2 hours with the 4-Imidazole carboxamide.Ice bath is cooled to 0 ℃, drips 1500ml saturated ammonium chloride solution termination reaction, and interior temperature control is at 5 ℃.With the gained solid filtering, filtrate layering, water layer ethyl acetate extraction three times (500ml * 3).The organic layer drying, evaporate to dryness is used the ether crystallization.The gained crystal is filtered, and washing gets yellow solid 48.2g.
Embodiment 3
The preparation of 4-(2, the 3-dimethylbenzoyl)-imidazoles:
(72.0g 3.00mol) covers with the 240ml tetrahydrofuran (THF) with magnesium chips.With 2, (350.0ml 2.58mol) is dissolved in the 800ml tetrahydrofuran (THF) 3-dimethyl bromobenzene.This drips of solution is added in the magnesium chips, continues after the initiation reaction slowly to drip, keep refluxing.After adding, reflux is intact to reactive magnesium, reacts to obtain Grignard reagent in 30 minutes again.
(50.0g 0.45mol) is suspended in the 1500ml pyridine, is heated to 60 ℃, drips above-mentioned Grignard reagent, drips the back insulation reaction 2 hours with the 4-Imidazole carboxamide.The ice bath cooling drips 1500ml saturated ammonium chloride solution termination reaction down, and interior temperature control is at 5 ℃.With the gained solid filtering, filtrate layering, water layer ethyl acetate extraction three times (500ml * 3).The organic layer drying, evaporate to dryness is used the ether crystallization.The gained crystal is filtered, and washing gets yellow solid 50.1g.
Embodiment 4
The preparation of 4-(2, the 3-dimethylbenzoyl)-imidazoles
(2.4g 0.10mol) covers with the 10ml tetrahydrofuran (THF) with magnesium chips.With 2, (12.5ml 0.092mol) is dissolved in the 40ml tetrahydrofuran (THF) 3-dimethyl bromobenzene.This drips of solution is added in the magnesium chips, continues after the initiation reaction slowly to drip, keep refluxing.After adding, reflux is intact to reactive magnesium, reacts to obtain Grignard reagent in 30 minutes again.
(5.0g 0.045mol) is suspended in the 150ml pyridine, is heated to 60 ℃, drips above-mentioned Grignard reagent, drips the back insulation reaction 2 hours with the 4-Imidazole carboxamide.The ice bath cooling drips 150ml saturated ammonium chloride solution termination reaction down, and interior temperature control is at 0 ℃.With the gained solid filtering, filtrate layering, water layer ethyl acetate extraction three times (50ml * 3).The organic layer drying, evaporate to dryness is used the ether crystallization.The gained crystal is filtered, and washing gets yellow solid 2.5g.
Embodiment 5
The preparation of 4-(2, the 3-dimethylbenzoyl)-imidazoles
(8.8g 0.37mol) covers with the 35ml tetrahydrofuran (THF) with magnesium chips.With 2, (45.0ml 0.33mol) is dissolved in the 120ml tetrahydrofuran (THF) 3-dimethyl bromobenzene.This drips of solution is added in the magnesium chips, continues after the initiation reaction slowly to drip, keep refluxing.After adding, reflux is intact to reactive magnesium, reacts to obtain Grignard reagent in 30 minutes again.
(5.0g 0.045mol) is suspended in the 150ml pyridine, is heated to 70 ℃, drips above-mentioned Grignard reagent, drips the back insulation reaction 2 hours with the 4-Imidazole carboxamide.The ice bath cooling adds 150ml saturated ammonium chloride solution termination reaction down, and interior temperature control is at 0 ℃.With the gained solid filtering, filtrate layering, water layer ethyl acetate extraction three times (50ml * 3).The organic layer drying, evaporate to dryness is used the ether crystallization.The gained crystal is filtered, and washing gets yellow solid 4.5g.
Embodiment 6
The preparation of 4-(2,3-dimethyl benzene ylmethyl)-imidazole hydrochloride (detomidine)
(15.0g 0.27mol) joins in the 60ml ethylene glycol, is heated to solid and all dissolves with potassium hydroxide.Add 4-(2, the 3-dimethylbenzoyl)-imidazoles (10.0g, 0.050mol), weight concentration is that (10ml 0.20mol), is heated to 50 ℃ to 100% hydrazine hydrate, continues to be heated to 150 ℃ and insulation reaction after the initiation reaction 1 hour.To react and produce moisture and steam, and follow the tracks of to react to raw material and disappear.Pressure reducing and steaming ethylene glycol carries out elutriation with 1000ml water.The dry crude product that gets.Activated carbon decolorizing, acetone recrystallization obtain white solid (4-(2,3-dimethyl benzene ylmethyl)-imidazoles) 5.0g, are the target product detomidine.
4-(2,3-dimethyl benzene ylmethyl)-imidazoles (5.0g) is added 100ml acetone, and heating for dissolving is cooled to room temperature.With 4ml 30%HCl-ethanolic soln 10ml acetone diluted, be added drop-wise in the aforementioned solution under the room temperature, there is solid to separate out.0 ℃ of crystallization 1 hour, crystal is filtered again, use washing with acetone, dry must Dormosedan 5.4g.HPLC detects purity 99.97%.

Claims (9)

1. prepare 4-(2; the 3-dimethylbenzoyl)-method of imidazoles; it is characterized in that; comprise the steps: the 4-Imidazole carboxamide is suspended under the organic bases solvent action; with 2; 4-(2, the 3-dimethylbenzoyl)-imidazoles is collected in the Grignard reagent reaction of 3-dimethyl bromobenzene then from reaction product.
2. method according to claim 1 is characterized in that, the 4-Imidazole carboxamide is suspended under the organic bases solvent action, 60-70 ℃ adds 2 down, and the Grignard reagent reaction of 3-dimethyl bromobenzene was reacted 1.5~2.5 hours then, be cooled to 0-10 ℃, add the saturated ammonium chloride solution termination reaction.
3. method according to claim 1 is characterized in that, described organic bases is selected from pyridine, triethylamine or 2,4-dimethylamino pyridine.
4. method according to claim 1 is characterized in that, 4-Imidazole carboxamide and 2, and the mol ratio of 3-dimethyl bromobenzene is 1: 2-1: 8.
5. method according to claim 1 is characterized in that, described 4-Imidazole carboxamide is separated by imidazole carboxylate ammonia and obtained.
6. the synthetic method of a detomidine is characterized in that, comprises the steps:
(a) the 4-Imidazole carboxamide is suspended under the organic bases solvent action, with 2,4-(2, the 3-dimethylbenzoyl)-imidazoles is collected in the reaction of the Grignard reagent of 3-dimethyl bromobenzene then from reaction product,
(b) with 4-(2, the 3-dimethylbenzoyl)-imidazoles in organic solvent, alkaline matter exists down and the reduction reagent react, collects 4-(2, the 3-dimethyl benzyl)-1H-imidazoles (detomidine) then from reaction product; The described original reagent of going back is a hydrazine hydrate.
7. method according to claim 6; it is characterized in that; the 4-Imidazole carboxamide is suspended in the organic bases solvent; 60-70 ℃ adds 2 down, and the Grignard reagent of 3-dimethyl bromobenzene reacted 1.5~2.5 hours then; be cooled to 0-10 ℃; add the saturated ammonium chloride solution termination reaction, from reaction product, collect 4-(2, the 3-dimethylbenzoyl)-imidazoles then.
8. method according to claim 7 is characterized in that, described organic bases is selected from pyridine, triethylamine or 2,4-dimethylamino pyridine.
9. method according to claim 7 is characterized in that, 4-Imidazole carboxamide and 2, and the mol ratio of 3-dimethyl bromobenzene is 1: 2-1: 8, described organic solvent is selected from ethylene glycol, 1,2-propylene glycol, 1, ammediol or neopentyl glycol;
Described alkaline matter is selected from potassium hydroxide, sodium hydroxide or calcium hydroxide, and the mol ratio of alkaline matter and 4-(2, the 3-dimethylbenzoyl)-imidazoles is 4-6: 1;
Temperature of reaction is 120~200 ℃, and the reaction times is 1~2 hour, and 4-(2, the 3-dimethylbenzoyl)-imidazoles is 1: 2~1: 6 with the mol ratio of going back original reagent.
CN2008102037170A2008-11-282008-11-28Method for preparing detomidine and the intermediate thereofExpired - Fee RelatedCN101747280B (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN2008102037170ACN101747280B (en)2008-11-282008-11-28Method for preparing detomidine and the intermediate thereof

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN2008102037170ACN101747280B (en)2008-11-282008-11-28Method for preparing detomidine and the intermediate thereof

Publications (2)

Publication NumberPublication Date
CN101747280A CN101747280A (en)2010-06-23
CN101747280Btrue CN101747280B (en)2011-11-09

Family

ID=42474962

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN2008102037170AExpired - Fee RelatedCN101747280B (en)2008-11-282008-11-28Method for preparing detomidine and the intermediate thereof

Country Status (1)

CountryLink
CN (1)CN101747280B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN101941944A (en)*2010-09-072011-01-12江阴希迪医药科技有限公司Synthesis method of veterinary drug anesthetic detomidine hydrochloride salt

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4443466A (en)*1979-08-071984-04-17Farmos-Yhtyma OY (Farmos Group Ltd.)4-Benzyl- and 4-benzoyl-substituted imidazole derivatives and use as medicaments
US4584383A (en)*1983-10-181986-04-22Farmos Yhtyma-OySubstituted 2-mercapto-imidazoles and their preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4443466A (en)*1979-08-071984-04-17Farmos-Yhtyma OY (Farmos Group Ltd.)4-Benzyl- and 4-benzoyl-substituted imidazole derivatives and use as medicaments
US4584383A (en)*1983-10-181986-04-22Farmos Yhtyma-OySubstituted 2-mercapto-imidazoles and their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Linas V.Kudzma et al.Expedient synthesis of 4(5)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole,the α2-adrenergic agonist medetomidine.《Synthesis》.1991,1021-1022.*

Also Published As

Publication numberPublication date
CN101747280A (en)2010-06-23

Similar Documents

PublicationPublication DateTitle
JP5395908B2 (en) Process for producing 4- (1-hydroxy-1-methylethyl) -2-propylimidazole-5-carboxylic acid ester
CN107311875A (en)The synthetic method of aramine
CN113527312B (en)Green synthesis method of sitagliptin intermediate
CN104130258A (en)Conversion method for dimers
CN110590587A (en)Synthetic method of 3-chloro-L-alanine methyl ester hydrochloride
CN101747280B (en)Method for preparing detomidine and the intermediate thereof
CN103304550A (en)Preparation method of Olmesartan Medoxomil
CN101845070B (en)Synthesis method of antineoplastic medicine capecitabine
CN104016954B (en) Preparation and purification method of nebivolol intermediate
CN102417482B (en)Method for synthesizing ozagrel ethyl ester or ozagrel methyl ester
CN102127006A (en)Production method of donepezil hydrochloride
CN105541910A (en)Diethyl p-toluenesulfonyloxy methylphosphonate synthesis method
CN102001920B (en) A kind of preparation method of pharmaceutical intermediate
JP2012524044A (en) Process for the preparation of 2,4,6-octatrien-1-acid and 2,4,6-octatrien-1-ol
CN113004245B (en)Preparation method of desloratadine
BargerLII.—The action of thionyl chloride and of phosphorus pentachloride on the methylene ethers of catechol derivatives
CN106496099A (en)The synthetic method of 2 [(2R, 6S) 6 [(2S) 2 hydroxyl, 2 phenethyl] 1 methyl piperidine] 1 1-Phenylethanone.
CN101696021A (en)Method for separating ammonium chloride and methanol from mother liquor subjected to alcohol precipitation and separation of glycine
CN106519083A (en)Preparation method of hydrogen phosphite for resin protection
CN105481831B (en)A kind of method for preparing dabigatran etexilate intermediate
CN105732613B (en)A kind of synthetic method of 9 demethyl (+) α dihydrotetrabenazineins
CN104817482A (en)2-substituted pyrrolidine compound, preparation method and application thereof in preparation of vildagliptin
CN105348148B (en)The method for preparing the oxalates of the impurity of dabigatran etexilate intermediate condensation product
CN112745314B (en)Preparation and synthesis method of aromatic amine compound with specific HIF-2 alpha inhibition effect
CN101333165B (en)Method for synthesizing monomethyl glutarate

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C14Grant of patent or utility model
GR01Patent grant
ASSSuccession or assignment of patent right

Owner name:SHANGHAI DESANO PHARMACEUTICAL CO., LTD.

Free format text:FORMER OWNER: SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO., LTD.

Effective date:20140331

Owner name:SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO., LTD.

Free format text:FORMER OWNER: SHANGHAI DISAINUO CHEMICAL PHARMACEUTICAL CO., LTD.

Effective date:20140331

C41Transfer of patent application or patent right or utility model
C56Change in the name or address of the patentee

Owner name:SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO., LTD.

Free format text:FORMER NAME: DISAINO MEDICINE DEVELOPMENT CO., LTD, SHANGHAI

CP01Change in the name or title of a patent holder

Address after:201203 Zhang Heng road Shanghai, Pudong New Area Zhangjiang hi tech Park No. 1479

Patentee after:SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd.

Patentee after:SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd.

Address before:201203 Zhang Heng road Shanghai, Pudong New Area Zhangjiang hi tech Park No. 1479

Patentee before:Shanghai Desano Pharmaceutical Holding Co.,Ltd.

Patentee before:SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd.

TR01Transfer of patent right

Effective date of registration:20140331

Address after:201203 Zhang Heng road Shanghai, Pudong New Area Zhangjiang hi tech Park No. 1479

Patentee after:SHANGHAI DESANO PHARMACEUTICALS INVESTMENT Co.,Ltd.

Patentee after:SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd.

Patentee after:SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd.

Address before:201203 Zhang Heng road Shanghai, Pudong New Area Zhangjiang hi tech Park No. 1479

Patentee before:SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP Co.,Ltd.

Patentee before:SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd.

CF01Termination of patent right due to non-payment of annual fee

Granted publication date:20111109

Termination date:20151128

CF01Termination of patent right due to non-payment of annual fee

[8]ページ先頭

©2009-2025 Movatter.jp